Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PPID | Q08752 | 1/20 | 0.32 |
| ▸ | CAD | P27708 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940851 | 1.00 | TDP1 (0.39) | TDP1SMN1; SMN2PLA2G2CL3MBTL1KMT2A | |
| SCHEMBL3936241 | 1.00 | TDP1 (0.39) | TDP1SMN1; SMN2PLA2G2CL3MBTL1KMT2A | |
| SCHEMBL3940848 | 1.00 | TDP1 (0.39) | TDP1SMN1; SMN2PLA2G2CL3MBTL1KMT2A | |
| SCHEMBL3935138 | 0.81 | TDP1 (0.44) | TDP1SMN1; SMN2L3MBTL1KMT2APOLB | |
| SCHEMBL11928922 | 0.73 | PLA2G2C (0.41) | SMN1; SMN2PLA2G2CL3MBTL1KMT2APOLB | |
| SCHEMBL10255206 | 0.73 | PLA2G2C (0.41) | SMN1; SMN2PLA2G2CL3MBTL1KMT2APOLB | |
| SCHEMBL18095072 | 0.73 | L3MBTL1 (0.49) | TDP1SMN1; SMN2L3MBTL1KMT2APOLB | |
| SCHEMBL3184286 | 0.72 | TAS1R3 (0.43) | PLA2G2CPOLBALDH1A1 | |
| SCHEMBL3184278 | 0.72 | TAS1R3 (0.43) | PLA2G2CPOLBALDH1A1 | |
| SCHEMBL5813383 | 0.72 | ALDH1A1 (0.60) | L3MBTL1KMT2APOLBALDH1A1PPID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046761-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008009750-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | TDP1 945/4885SMN1; SMN2 1039/4885PLA2G2C 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.